CN108368115A - 吡咯并嘧啶化合物的盐 - Google Patents
吡咯并嘧啶化合物的盐 Download PDFInfo
- Publication number
- CN108368115A CN108368115A CN201680072397.2A CN201680072397A CN108368115A CN 108368115 A CN108368115 A CN 108368115A CN 201680072397 A CN201680072397 A CN 201680072397A CN 108368115 A CN108368115 A CN 108368115A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- compound shown
- formula
- pharmaceutical composition
- janus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Description
Claims (13)
- 式Ⅰ所示化合物的盐酸盐:
- 如权利要求1所述的式Ⅰ所示化合物的盐酸盐,其中式Ⅰ所示化合物与HCl的物质的量之比为1:0.5~3。
- 如权利要求2所述的式Ⅰ所示化合物的盐酸盐,其中式Ⅰ所示化合物与HCl的物质的量之比为1:1。
- 一种药物组合物,其包含权利要求1-3中任一项所述的式Ⅰ所示化合物的盐酸盐。
- 权利要求1-3中任一项所述的式Ⅰ所示化合物的盐酸盐在制备治疗两面神激酶介导的疾病的药物中的用途。
- 一种用于治疗两面神激酶介导的疾病的方法,包括给予患者治疗有效量的权利要求1-3中任一项所述的式Ⅰ所示化合物的盐酸盐。
- 用于治疗两面神激酶介导的疾病的权利要求1-3中任一项所述的式I所示化合物的盐酸盐。
- 用于治疗两面神激酶介导的疾病的权利要求4所述的药物组合物。
- 如权利要求5所述的用途,如权利要求6所述的方法,如权利要求7所述的盐酸盐或如权利要求8所述的药物组合物,其中所述两面神激酶介导的疾病为肿瘤。
- 如权利要求9所述的用途、方法、盐酸盐或药物组合物,其中所述肿瘤选自淋巴瘤或白血病。
- 如权利要求10所述的用途、方法、盐酸盐或药物组合物,其中所述淋巴瘤选自霍奇金病或非霍奇金淋巴瘤。
- 如权利要求11所述的用途、方法、盐酸盐或药物组合物,其中所述非霍奇金淋巴瘤选自 B-细胞淋巴瘤或T-细胞淋巴瘤。
- 如权利要求10所述的用途、方法、盐酸盐或药物组合物,其中所述白血病选自急性淋巴细胞白血病、慢性淋巴细胞白血病、急性粒细胞白血病或慢性粒细胞白血病。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510932786 | 2015-12-15 | ||
CN2015109327865 | 2015-12-15 | ||
PCT/CN2016/109835 WO2017101777A1 (zh) | 2015-12-15 | 2016-12-14 | 吡咯并嘧啶化合物的盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108368115A true CN108368115A (zh) | 2018-08-03 |
CN108368115B CN108368115B (zh) | 2020-01-03 |
Family
ID=59055858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680072397.2A Active CN108368115B (zh) | 2015-12-15 | 2016-12-14 | 吡咯并嘧啶化合物的盐 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108368115B (zh) |
WO (1) | WO2017101777A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3904356A4 (en) | 2018-12-24 | 2022-09-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND |
CN114981272A (zh) * | 2020-03-09 | 2022-08-30 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 |
AU2022296552A1 (en) * | 2021-06-21 | 2024-01-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease |
WO2023179547A1 (zh) * | 2022-03-21 | 2023-09-28 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007070514A1 (en) * | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
-
2016
- 2016-12-14 WO PCT/CN2016/109835 patent/WO2017101777A1/zh active Application Filing
- 2016-12-14 CN CN201680072397.2A patent/CN108368115B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007070514A1 (en) * | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN108368115B (zh) | 2020-01-03 |
WO2017101777A1 (zh) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11007197B2 (en) | EGFR modulators and uses thereof | |
CN104395308B (zh) | N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢-吡喃-4-基氨基)-苯甲酰胺的制备方法 | |
CN101072779B (zh) | 2,4(4,6)嘧啶衍生物 | |
EP3269719B1 (en) | Crystal form of jak inhibitor and preparation method thereof | |
CN101273989B (zh) | 一类小檗胺衍生物及其盐的应用 | |
CN108368115A (zh) | 吡咯并嘧啶化合物的盐 | |
JP2014517042A (ja) | ベンダムスチンおよび/またはリツキシマブと共にピリドピリミジノンpi3k/mtor阻害剤を使用する、悪性血液疾患を治療するための併用療法 | |
CN112979528B (zh) | 一种替加色罗水溶性有机酸盐及其制备方法与应用 | |
US20220054492A1 (en) | Combination therapies | |
CN107163026A (zh) | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 | |
JP2020506964A (ja) | キナーゼ活性を抑制するための(ヘテロ)アリールアミド類化合物 | |
US10323035B2 (en) | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof | |
EP4319754A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
US20220096482A1 (en) | Combination therapies | |
JP2022522395A (ja) | 選択的エストロゲン受容体分解剤の新規な塩 | |
CN108358894B (zh) | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 | |
CN108602800B (zh) | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 | |
EP2701690A1 (en) | Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor | |
AU2022361380A1 (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
CN109111439A (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
WO2014010948A1 (ko) | 아자티오프린을 유효성분으로 함유하는 뇌종양 또는 테모달 내성 교모세포종 예방 또는 치료용 약학적 조성물 | |
CN107474043A (zh) | 烟酸衍生物及其制备方法与用途 | |
CN105732642B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
EP2585063A1 (en) | Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone | |
CN105753869B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190530 Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd. Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369 Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd. Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Shouyao holding (Beijing) Co.,Ltd. Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |